Division of Oral and Maxillofacial Surgery, Dental School, University of Pernambuco (UPE), Arnóbio Marques St., 310, Recife, PE, 50100-130, Brazil.
Federal University of Pernambuco (UFPE), Recife, PE, Brazil.
Eur J Clin Pharmacol. 2023 May;79(5):589-607. doi: 10.1007/s00228-023-03475-7. Epub 2023 Mar 22.
We aimed (1) to systematically review the efficacy of transdermal nicotine patches (NP) for postoperative analgesia, (2) to establish the current quality of evidence and assist clinical decision-making on the subject, and (3) to identify methodological limitations and the need for more well-designed studies.
We searched six electronic databases, protocol records, and other sources without date or language restriction until March 2022. To develop the search strategy, we formulated a clinical question by using the PICOD method. Eligibility criteria included randomised placebo-controlled trials on the analgesic potential of NP for surgical procedures. This systematic review followed the PRISMA 2020 statement, and we registered the protocol in PROSPERO (#CRD42020205956).
We included 10 randomised placebo-controlled trials (535 patients). The NP administered before induction of anaesthesia and at beginning of surgery reduced the pain immediately after surgery (-0.38; 95% confidence interval [CI]: -0.73 to -0.02), and 6 h (-0.34; 95% CI: -0.68 to -0.01), 12 h (-0.43; 95% CI: -0.71 to -0.15) and 24 h (-0.35; 95%CI: -0.59 to -0.10) after surgery, compared with the placebo patch (PP) group. Sensitivity testing suggests that opioid use could underestimate NP analgesia. Late demand for the first analgesic and consumption of rescue analgesics tended to be lower in the NP group.
The current findings suggest, with low certainty of evidence, the analgesic potential of NP for surgical procedures.
Perioperative use of NP significantly improved postoperative pain, even when opioids were administered or prescribed. Nevertheless, the clinical relevance should be interpreted with caution, owing to the effect sizes of the summary measures and methodological issues. The analgesic potential of NP as an adjuvant therapy to regulate pain and acute inflammation may offer certain clinical advantages, thus warranting further investigation.
我们旨在(1)系统地综述透皮尼古丁贴片(NP)在术后镇痛中的疗效,(2)确定当前证据质量并协助该主题的临床决策,以及(3)识别方法学局限性和对更多精心设计研究的需求。
我们无日期或语言限制地检索了六个电子数据库、方案记录和其他来源,直到 2022 年 3 月。为了制定搜索策略,我们使用 PICOD 方法制定了一个临床问题。纳入标准包括关于 NP 对手术程序镇痛潜力的随机安慰剂对照试验。本系统评价遵循 PRISMA 2020 声明,并在 PROSPERO 中注册了方案(#CRD42020205956)。
我们纳入了 10 项随机安慰剂对照试验(535 名患者)。NP 在诱导麻醉前和手术开始时给药,可减少术后即刻疼痛(-0.38;95%置信区间 [CI]:-0.73 至-0.02),6 小时(-0.34;95%CI:-0.68 至-0.01),12 小时(-0.43;95%CI:-0.71 至-0.15)和 24 小时(-0.35;95%CI:-0.59 至-0.10),与安慰剂贴片(PP)组相比。敏感性测试表明,阿片类药物的使用可能低估了 NP 的镇痛作用。NP 组对第一剂镇痛药的需求延迟和使用补救性镇痛药的倾向较低。
目前的研究结果表明,NP 在手术中的镇痛潜力存在低确定性证据。
围手术期使用 NP 可显著改善术后疼痛,即使给予或开处了阿片类药物。然而,由于汇总测量的效应大小和方法学问题,应谨慎解释临床相关性。NP 作为调节疼痛和急性炎症的辅助治疗的镇痛潜力可能具有某些临床优势,因此值得进一步研究。